Clinical efficacy of concomitant administration of haloperidol and midazolam through continuous infusion for the management of nausea and vomiting in a delirious patient with peritoneal carcinomatosis: A case report
10.2512/jspm.4.312
- VernacularTitle:がん性腹膜炎の難治性嘔吐とせん妄にハロペリド‐ルとミダゾラムの併用が奏効した１例
- Author:
Katsuo Sugiyama
;
Akira Ishikawa
;
Tadashi Watanabe
;
Sumie Takahashi
;
Tomiko Terashima
;
Namiko Ooe
;
Mikiko Gotou
- Publication Type:Journal Article
- Keywords:
nausea and vomiting;
delirium;
sedation;
haloperidol;
midazolam
- From:Palliative Care Research
2009;4(1):312-316
- CountryJapan
- Language:Japanese
-
Abstract:
It is well known that haloperidol is effective in the management of nausea and vomiting in cancer patients and that midazolam is used for inducing sedation in patients with delirium. Both the drugs are frequently used in a clinical setting, but there have been only few reports thus far on the concomitant administration of these 2 drugs. We report the case of a patient with massive ascites due to peritoneal carcinomatosis who had severe nausea and vomiting and went into a delirious state. This patient received a concomitant continuous infusion of haloperidol and midazolam for the management of these symptoms. Both haloperidol (up to 1.87mg/h) and midazolam (up to 1.87mg/h) were infused intravenously. For about 20 days, the nausea, vomiting and delirium were well under control without the development of any life threatening toxicities. Concomitant haloperidol and midazolam infusion was found to be a safe and effective therapy for the management of nausea and vomiting in the patient. Palliat Care Res 2009; 4(1): 312-316
